SGLT2 Inhibitors Have Similar Benefits to GLP-1 Receptor Agonists for Myocardial Infarction or Stroke but Greater Benefits for Hospitalization for Heart Failure in Patients with Type 2 Diabetes
Practice guidelines recommend considering sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients who have both diabetes and atherosclerotic cardiovascular disease (CVD). The choice between the drug classes is left to the physician, except that SGLT2 inhibitors are advised for patients with a history of heart failure.